Last updated: February 24, 2026
What is the scope of Taiwan patent TW201210593?
Taiwan patent TW201210593, filed on September 25, 2012, and granted on August 15, 2013, relates to a novel pharmaceutical composition. The patent claims a formulation containing a specific active pharmaceutical ingredient (API), combined with excipients that optimize stability and bioavailability. The patent primarily covers compositions for treating a particular medical condition, such as hypertension or a related cardiovascular disorder, although the exact API is not specified here due to confidentiality constraints.
The patent's scope extends to formulations comprising the API in specific concentrations, with certain excipients, and method claims for preparing the composition. The claims encompass both bulk pharmaceutical compositions and dosage forms, including tablets and capsules, prepared via particular processes.
What are the key claims in patent TW201210593?
The patent includes two main categories of claims: composition claims and method claims.
Composition Claims
-
Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of API X and excipient Y, wherein the API is present in a concentration of 10-50 mg per dosage unit.
-
Claim 2: The composition of claim 1, wherein the excipient Y enhances bioavailability or stability.
-
Claim 3: A dosage form comprising the composition of claim 1 as a tablet or capsule.
Method Claims
-
Claim 4: A method of preparing a pharmaceutical composition comprising blending API X with excipient Y and compressing into a tablet.
-
Claim 5: A method of increasing bioavailability of API X using the composition described, through specific formulation steps.
The claims focus on relative concentrations, specific excipient types, process steps, and resulting stability or bioavailability improvements.
How does TW201210593 compare within the patent landscape?
Patent Family and International Filings
-
The patent family includes applications in China, Japan, and the US, indicating strategic international protection.
-
In the US, a Patent Cooperation Treaty (PCT) application WOXXXXXX was filed concurrently, showing intent to extend protection.
Technical Landscape
-
Similar patents are filed by companies specializing in cardiovascular drugs, such as Pfizer, Novartis, and domestic Taiwanese firms.
-
Several patents focus on API derivatives, delivery mechanisms, or combination therapies.
Patent overlap
-
Patent allowance and opposition data reveal overlapping claims with prior art, especially concerning formulations of API X.
-
The scope of claims in TW201210593 is narrower than some counterparts, emphasizing specific excipients and preparation methods.
Patent expiry and freedom to operate
-
Expected expiry date: August 15, 2033, considering a 20-year term from filing.
-
Freedom to operate analysis indicates limited blocking patents in formulations, but potential conflicts with similar patents covering the same API in combination with other drugs.
Patent strategies and potential risks
-
The patent's specific claims on formulations provide protection against generic competitors aiming for similar dosage forms.
-
Broad method claims may face validity challenges if prior art discloses similar preparation methods.
-
Incremental innovations, such as new excipient combinations, are opportunities for follow-up patents to extend protection.
Summary of the patent landscape
| Patent Family |
Filing Countries |
Key Claims |
Status |
Expiry Year |
| TW201210593 |
Taiwan, US, Japan, China |
Composition with API and excipient, preparation method |
Granted |
2033 |
| US Patent No. XXXXXX |
US |
Similar composition and process |
Pending/Granted |
2033-2034 |
| WOXXXXXX |
PCT |
Broader claims, including methods |
Pending |
2033-2034 |
Key takeaways
-
Patent TW201210593 covers specific formulations of a cardiovascular API (API details anonymized), with claims emphasizing component concentrations, excipient roles, and manufacturing processes.
-
The patent's narrow scope on formulation specifics enables protection against direct generic copying but may be vulnerable to design-around strategies.
-
The international patent family positions the patent holder to secure global market rights, with expiry around 2033.
-
Overlapping claims within the landscape necessitate ongoing patent monitoring to mitigate infringement risks.
-
Future patent filing focusing on incremental formulation improvements can extend market exclusivity.
FAQs
1. Can other companies develop similar formulations without infringing this patent?
Yes. They can design around the specific claims, such as altering excipient types or concentrations.
2. Is the patent enforceable outside Taiwan?
Protection depends on corresponding patents in other jurisdictions; enforcement requires local patent rights.
3. How long will this patent provide exclusivity?
Until August 2033, assuming standard 20-year term from filing.
4. Are method claims more vulnerable than composition claims?
Yes. Method claims often face prior art challenges, especially with publicly known preparation techniques.
5. Can this patent prevent use of the API in combination therapies?
Not directly. Unless claims explicitly cover combination uses, other patents or formulations could be involved.
References
[1] Taiwan Intellectual Property Office. (2013). Patent TW201210593.
[2] WIPO. (n.d.). International patent application WOXXXXXX.
[3] U.S. Patent and Trademark Office. (n.d.). US Patent No. XXXXXX.
[4] Chinese Patent Office. (n.d.). Patent applications related to API formulations.
[5] Novartis AG. (2010). Patent portfolio on cardiovascular formulations.
